Cargando…

Relapsing/remitting type 1 diabetes

AIMS/HYPOTHESIS: Type 1 diabetes is believed to be an autoimmune disease associated with irreversible loss of insulin secretory function that follows a chronic progressive course. However, it has been speculated that relapsing/remitting disease progression may occur in type 1 diabetes. METHODS: We r...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Megen, Kayleigh M., Spindler, Matthew P., Keij, Fleur M., Bosch, Ineke, Sprangers, Fleur, van Royen-Kerkhof, Annet, Nikolic, Tatjana, Roep, Bart O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448902/ https://www.ncbi.nlm.nih.gov/pubmed/28835984 http://dx.doi.org/10.1007/s00125-017-4403-3

Ejemplares similares

Activated Mesenchymal Stromal Cells Process and Present Antigens Regulating Adaptive Immunity
por: van Megen, Kayleigh M., et al.
Publicado: (2019)

A Future for Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2018)

1,25-dihydroxyvitamin D3 induces stable and reproducible therapeutic tolerogenic dendritic cells with specific epigenetic modifications
por: van Megen, Kayleigh M., et al.
Publicado: (2021)

The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosis
por: Singhal, Tarun, et al.
Publicado: (2016)

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
por: Daruwalla, Cyrus, et al.
Publicado: (2023)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

Regulatory Multitasking of Tolerogenic Dendritic Cells – Lessons Taken from Vitamin D3-Treated Tolerogenic Dendritic Cells
por: Nikolic, Tatjana, et al.
Publicado: (2013)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Anti–PD-1 Therapy–Associated Type 1 Diabetes in a Pediatric Patient With Relapsed Classical Hodgkin Lymphoma
por: Samoa, Raynald A., et al.
Publicado: (2020)

Where, How, and When: Positioning Posttranslational Modification Within Type 1 Diabetes Pathogenesis
por: McLaughlin, Rene J., et al.
Publicado: (2016)

Medical Students’ Perspectives on Online Proctoring During Remote Digital Progress Test
por: Meulmeester, Fleur L., et al.
Publicado: (2021)

Translating Mechanism of Regulatory Action of Tolerogenic Dendritic Cells to Monitoring Endpoints in Clinical Trials
por: Suwandi, Jessica S., et al.
Publicado: (2017)

Experiences and preferences towards collecting a urine and cervicovaginal self-sample among women attending a colposcopy clinic
por: Schaafsma, Mirte, et al.
Publicado: (2022)

Functional Impact of Risk Gene Variants on the Autoimmune Responses in Type 1 Diabetes
por: Gootjes, Chelsea, et al.
Publicado: (2022)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Innate and adaptive immunity to human beta cell lines: implications for beta cell therapy
por: van der Torren, Cornelis R., et al.
Publicado: (2015)

Congenital beta cell defects are not associated with markers of islet autoimmunity, even in the context of high genetic risk for type 1 diabetes
por: Wyatt, Rebecca C., et al.
Publicado: (2022)

Diminished seroconversion following a single SARS-COV-2 vaccine in ocrelizumab-treated relapsing-remitting multiple sclerosis patients
por: Georgieva, Zoya G, et al.
Publicado: (2021)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Real-world outcomes of teriflunomide in relapsing–remitting multiple sclerosis: a prospective cohort study
por: Zhang, Yao, et al.
Publicado: (2022)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
por: Braune, Stefan, et al.
Publicado: (2015)

Leg blood flow measurements using venous occlusion plethysmography during head-up tilt
por: Kooijman, Miriam, et al.
Publicado: (2007)

Work Participation and Executive Abilities in Patients with Relapsing-Remitting Multiple Sclerosis
por: van der Hiele, Karin, et al.
Publicado: (2015)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Relapsing and remitting viral diseases of the nervous system
por: Johnson, Richard T.
Publicado: (1984)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Relapsing–remitting painful ophthalmoplegia due to orbital myositis
por: Guaschino, E., et al.
Publicado: (2005)

Intra-pancreatic tissue-derived mesenchymal stromal cells: a promising therapeutic potential with anti-inflammatory and pro-angiogenic profiles
por: Khiatah, Bashar, et al.
Publicado: (2019)

Rapid relapse to smoking following hospital discharge()
por: Mussulman, Laura M., et al.
Publicado: (2019)

Self-Glycolipids Modulate Dendritic Cells Changing the Cytokine Profiles of Committed Autoreactive T Cells
por: Buschard, Karsten, et al.
Publicado: (2012)

Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis
por: Stühler, E., et al.
Publicado: (2020)

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study
por: Bar-Or, Amit, et al.
Publicado: (2018)

Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis
por: Becker III, Russell V., et al.
Publicado: (2011)

Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools
por: Wienke, Judith, et al.
Publicado: (2018)

Experiences with the implementation of a national teaching qualification in university medical centres and veterinary medicine in the Netherlands
por: Molenaar, Willemina M. (Ineke), et al.
Publicado: (2015)

Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later
por: Jongen, Peter Joseph, et al.
Publicado: (2016)

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Newsome, Scott D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_r4kjahbipoe5chmhu5uctsh5rl